Global Epidemiological Impact of PNPLA3 I148M on Liver Disease
Liver International · 2025-03 · 45 (3)
DOI: 10.1111/liv.16123 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 07.10.2024. Verfasst von Julia Kozlitina und 1 weiteren Autor:innen. Beteiligte Einrichtung: Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Lipase, Membrane Proteins, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agencia Nacional de Promoción Científica y Tecnológica Argentina, FONCyT.
Abstract (Originalsprache)
The prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) has increased exponentially over the past three decades, in parallel with the global rise in obesity and type 2 diabetes. It is currently the most common cause of liver‐related morbidity and mortality. Although obesity has been identified as a key factor in the increased prevalence of MASLD, individual differences in susceptibility are significantly influenced by genetic factors. PNPLA3 I148M (rs738409 C>G) is the variant with the greatest impact on the risk of developing progressive MASLD and likely other forms of steatotic liver disease. This variant is prevalent across the globe, with the risk allele (G) frequency exhibiting considerable variation. Here, we review the contribution of PNPLA3 I148M to global burden and regional differences in MASLD prevalence, focusing on recent evidence emerging from population‐based sequencing studies and prevalence assessments. We calculated the population attributable fraction (PAF) as a means of quantifying the impact of the variant on MASLD. Furthermore, we employ quantitative trait locus (QTL) analysis to ascertain the associations between rs738409 and a range of phenotypic traits. This analysis suggests that these QTLs may underpin pleiotropic effects on extrahepatic traits. Finally, we outline potential avenues for further research and identify key areas for investigation in future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
- Clinical and Molecular Hepatology, Translational Health Research Center (CENITRES), Maimónides University, Buenos Aires, Argentina.
ORCID-Profile: Julia Kozlitina, Silvia Sookoian
Förderung
- Agencia Nacional de Promoción Científica y Tecnológica Argentina, FONCyT
Zitieren
APA
Kozlitina, J., & Sookoian, S. (2025). Global Epidemiological Impact of PNPLA3 I148M on Liver Disease. Liver International, 45(3). https://doi.org/10.1111/liv.16123
Vancouver
Kozlitina J, Sookoian S. Global Epidemiological Impact of PNPLA3 I148M on Liver Disease. Liver International. 2025;45(3). doi:10.1111/liv.16123
BibTeX
@article{Kozlitina2025,
author = {Kozlitina, Julia and Sookoian, Silvia},
title = {Global Epidemiological Impact of PNPLA3 I148M on Liver Disease},
journal = {Liver International},
year = {2025},
volume = {45},
number = {3},
doi = {10.1111/liv.16123}
}
EUVIMED